A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer

NCT00298688 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Gefitinib

Sponsor

AstraZeneca